Toggle Main Menu Toggle Search

Open Access padlockePrints

Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer

Lookup NU author(s): Dr Pasquale RescignoORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).


Abstract

© 2024 The Author(s). Although hypercoagulability is commonly associated with malignancies, whether coagulation factors directly affect tumor cell proliferation remains unclear. Herein, by performing single-cell RNA sequencing (scRNA-seq) of the prostate tumor microenvironment (TME) of mouse models of castration-resistant prostate cancer (CRPC), we report that immunosuppressive neutrophils (PMN-MDSCs) are a key extra-hepatic source of coagulation factor X (FX). FX activation within the TME enhances androgen-independent tumor growth by activating the protease-activated receptor 2 (PAR2) and the phosphorylation of ERK1/2 in tumor cells. Genetic and pharmacological inhibition of factor Xa (FXa) antagonizes the oncogenic activity of PMN-MDSCs, reduces tumor progression, and synergizes with enzalutamide therapy. Intriguingly, F10high PMN-MDSCs express the surface marker CD84 and CD84 ligation enhances F10 expression. Elevated levels of FX, CD84, and PAR2 in prostate tumors associate with worse survival in CRPC patients. This study provides evidence that FXa directly promotes cancer and highlights additional targets for PMN-MDSCs for cancer therapies.


Publication metadata

Author(s): Cali B, Troiani M, Bressan S, Attanasio G, Merler S, Moscarda V, Mosole S, Ricci E, Guo C, Yuan W, Gallagher L, Lundberg A, Bernett I, Figueiredo I, Arzola RA, Abreut EB, D'Ambrosio M, Bancaro N, Brina D, Zumerle S, Pasquini E, Maddalena M, Lai P, Colucci M, Pernigoni N, Rinaldi A, Minardi D, Morlacco A, Moro FD, Sabbadin M, Galuppini F, Fassan M, Ruschoff JH, Moch H, Rescigno P, Francini E, Saieva C, Modesti M, Theurillat J-P, Gillessen S, Wilgenbus P, Graf C, Ruf W, De Bono J, Alimonti A

Publication type: Article

Publication status: Published

Journal: Cancer Cell

Year: 2024

Volume: 42

Issue: 10

Pages: 1676-1692.e11

Print publication date: 14/10/2024

Online publication date: 19/09/2024

Acceptance date: 22/08/2024

Date deposited: 07/11/2024

ISSN (print): 1535-6108

ISSN (electronic): 1878-3686

Publisher: Cell Press

URL: https://doi.org/10.1016/j.ccell.2024.08.018

DOI: 10.1016/j.ccell.2024.08.018

Data Access Statement: Single-cell RNA-seq and RNA-seq data generated for this study have been deposited at GEO and are publicly available. GEO accession numbers are listed in the key resources table. The accession numbers for the other existing, publicly available, scRNA-seq and RNA-seq datasets analyzed for this study are listed in the key resources table.

PubMed id: 39303726


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Fidinam Foundation
ERC-CoG 683136
German Research Foundation (project number 318346496 and SFB1292/2 TP10)
ISREC Foundation
Novartis Foundation
SNSF Sinergia grant 202302
PCF-19CHAL08
SNSF Excellence grant 201274

Share